金吾财讯 | 药明巨诺(02126)公布，宣布中国国家药品监督管理局(“NMPA”)已受理其细胞免疫治疗产品倍诺达(瑞基奥仑赛注射液)用于二线治疗复发或难治成人大B细胞淋巴瘤(“r/rLBCL”)患者的新适应症上市许可申请(“sBLA”)。这是药明巨诺针对倍诺达递交的第四项上市许可申请。于2025年1月，倍诺达被NMPA授予二线治疗r/rLBCL的突破性治疗药物认定。
金吾财讯 | 药明巨诺(02126)公布，宣布中国国家药品监督管理局(“NMPA”)已受理其细胞免疫治疗产品倍诺达(瑞基奥仑赛注射液)用于二线治疗复发或难治成人大B细胞淋巴瘤(“r/rLBCL”)患者的新适应症上市许可申请(“sBLA”)。这是药明巨诺针对倍诺达递交的第四项上市许可申请。于2025年1月，倍诺达被NMPA授予二线治疗r/rLBCL的突破性治疗药物认定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.